Literature DB >> 9819017

A study of losartan, alone or with hydrochlorothiazide vs nifedipine GITS in elderly patients with diastolic hypertension.

P R Conlin1, M Elkins, C Liss, A J Vrecenak, E Barr, J M Edelman.   

Abstract

We conducted a randomised, double-blind, parallel design study comparing the efficacy and tolerability of the angiotensin II receptor antagonist, losartan, alone or with low-dose hydrochlorothiazide (HCTZ) to the dihydropyridine calcium channel blocker, nifedipine GITS (gastro-intestinal therapeutic system), in elderly patients (> or =65 years old) with a diastolic blood pressure (DBP) between 95 and 115 mm Hg. After a placebo wash out period, 140 patients were randomly assigned to receive either losartan 50 mg or nifedipine GITS 30 mg. Patients were evaluated at 4-week intervals during a 12-week treatment period. Patients receiving losartan had HCTZ 12.5 mg added and increased to 25 mg to reduce DBP <90 mm Hg. Patients receiving nifedipine GITS had their dose increased to 60 mg and 90 mg to reduce DBP <90 mm Hg. Efficacy, tolerability and quality of life were assessed during the 12 weeks on each regimen. Patients treated with the losartan regimen (n = 73) had reductions in trough sitting DBP of -10, -13, and -13 mm Hg after 4, 8, and 12 weeks of therapy, respectively. Patients receiving the nifedipine GITS regimen (n = 67) had DBP reductions of -14, -15, and -15 mm Hg, respectively. There were no significant differences in the DBP response between the treatment groups except at week 4 (P < 0.05). Similar reductions in systolic BP (SBP) between the two treatment groups were observed at all time points. The percentages of patients in the two treatment groups reaching goal DBP (<90 mm Hg or DBP > or =90 mm Hg with a reduction from a baseline of > or =10 mm Hg) were comparable (81% on the losartan regimen and 90% on the nifedipine GITS regimen). There were significantly more adverse events reported in patients receiving nifedipine GITS when compared to the losartan regimen (54% vs 36%, P < 0.05). A patient-reported symptom inventory also showed that swollen ankles was bothersome in significantly more patients treated with the nifedipine GITS regimen when compared to the losartan regimen (24% vs 5%, P = 0.001). Thus, in elderly patients with diastolic hypertension, a regimen of losartan alone or with HCTZ has similar efficacy to a regimen of nifedipine GITS with greater tolerability and less symptom bother due to swollen ankles.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819017     DOI: 10.1038/sj.jhh.1000687

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  8 in total

Review 1.  Losartan: a review of its use, with special focus on elderly patients.

Authors:  K L Simpson; K J McClellan
Journal:  Drugs Aging       Date:  2000-03       Impact factor: 3.923

2.  Spectrum of use for the angiotensin-receptor blocking drugs.

Authors:  M E Fabiani; C I Johnston
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 3.  The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Authors:  G Neil Thomas; Paul Chan; Brian Tomlinson
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure.

Authors:  J P Baguet; B Legallicier; P Auquier; S Robitail
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.

Authors:  Anthony M Heagerty; Jean-Michel Mallion
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 6.  Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics.

Authors:  Paolo Palatini
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-02       Impact factor: 3.738

Review 7.  Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Authors:  Katherine F Croom; Keri Wellington
Journal:  Drugs       Date:  2006       Impact factor: 11.431

8.  Simultaneous Determination of Valsartan and Hydrochlorothiazide in Tablets by RP-HPLC.

Authors:  D F Tian; X L Tian; T Tian; Z Y Wang; F K Mo
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.